SCHEMBL5033243

SCHEMBL5033243

[CH2]c1ccc(C)nc1O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL249139 0.76
SCHEMBL6629186 0.74
Methane SCHEMBL6376219 0.74 KDM4E (0.54)
SCHEMBL17431328 0.74
SCHEMBL16437203 0.71 KDM4E (0.52)
SCHEMBL12806957 0.71 KDM4E (0.42)
SCHEMBL6834128 0.70
SCHEMBL10304906 0.70
SCHEMBL7923017 0.70
SCHEMBL220418 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1906958-A2 PYRAZOLO[3,4-B]PYRIDIN-2-YL]-BENZOIC ACID DERIVATIVES AS HIV INTEGRASE INHIBITORS Ambrilia Biopharma Inc. (CA) 2008-04-09 EP claimed
WO-2007000043-A2 PYRAZOLO[3,4-B]PYRIDIN-2-YL]-BENZOIC ACID DERIVATIVES AS HIV INTEGRASE INHIBITORS AMBRILIA BIOPHARMA INC. (CA) 2007-01-04 WO claimed
US-6777535-B1 USEFUL FOR TREATING CONDITIONS WHICH ARISE OR ARE EXACERBATED BY ANGIOGENESIS ABBOTT LABORATORIES 2004-08-17 US claimed
US-6753408-B1 DRUGS USED FOR THERAPY ABBVIE INC. 2004-06-22 US claimed
EP-1242455-A1 N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY Abbott Laboratories (US) 2002-09-25 EP claimed
WO-2001038397-A1 N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2001-05-31 WO claimed
EP-1906958-A2 PYRAZOLO[3,4-B]PYRIDIN-2-YL]-BENZOIC ACID DERIVATIVES AS HIV INTEGRASE INHIBITORS Ambrilia Biopharma Inc. (CA) 2008-04-09 EP disclosed
WO-2007000043-A2 PYRAZOLO[3,4-B]PYRIDIN-2-YL]-BENZOIC ACID DERIVATIVES AS HIV INTEGRASE INHIBITORS AMBRILIA BIOPHARMA INC. (CA) 2007-01-04 WO disclosed